Biomarkers predictive of response to pembrolizumab in head and neck cancer.
David G PfisterRobert I HaddadFrancis P WordenJared WeissRanee MehraLaura Q M ChowStephen V LiuHyunseok KangNabil F SabaLori J WirthAmmar SukariErminia MassarelliMark AyersAndrew AlbrightAndrea L WebberRobin MoggJared LuncefordLingkang HuangRazvan CristescuJonathan ChengTanguy Y SeiwertJoshua M BaumlPublished in: Cancer medicine (2022)
GEP, assessed alone or together, may be useful for characterizing clinical response to pembrolizumab in R/M HNSCC.
Keyphrases